Braun Stacey Associates Decreased By $1.63 Million Its Duke Energy Com Ne (DUK) Holding; Last Week Alnylam Pharmaceuticals, Inc. (ALNY) Analysts

Duke Energy Corporation (NYSE:DUK) Logo

Among 7 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Alnylam Pharmaceuticals had 8 analyst reports since September 13, 2018 according to SRatingsIntel. Morgan Stanley maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, September 28. Morgan Stanley has “Equal-Weight” rating and $87 target. The rating was maintained by BMO Capital Markets with “Outperform” on Tuesday, October 16. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Cantor Fitzgerald on Wednesday, November 28. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Thursday, September 13 by Stifel Nicolaus. See Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) latest ratings:

23/01/2019 Broker: UBS Rating: Neutral Initiates Coverage On
18/12/2018 Broker: Guggenheim Rating: Buy New Target: $105 Initiates Coverage On
28/11/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $135.0000 Maintain
28/11/2018 Broker: Leerink Swann Rating: Market Perform New Target: $63 Initiates Coverage On
16/10/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $125 New Target: $124 Maintain
01/10/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $135 Initiates Coverage On
28/09/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $93 New Target: $87 Maintain
13/09/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $123 New Target: $117 Maintain

Braun Stacey Associates Inc decreased Duke Energy Corporation Com Ne (DUK) stake by 27.91% reported in 2018Q3 SEC filing. Braun Stacey Associates Inc sold 20,317 shares as Duke Energy Corporation Com Ne (DUK)’s stock rose 9.96%. The Braun Stacey Associates Inc holds 52,488 shares with $4.20M value, down from 72,805 last quarter. Duke Energy Corporation Com Ne now has $63.87 billion valuation. The stock decreased 0.71% or $0.64 during the last trading session, reaching $89.59. About 5.28 million shares traded or 51.69% up from the average. Duke Energy Corporation (NYSE:DUK) has risen 2.97% since February 14, 2018 and is uptrending. It has outperformed by 2.97% the S&P500. Some Historical DUK News: 22/03/2018 – Duke Energy: Sees Investing $11B Over 2017-2026 in New Natural Gas-Fired, Wind and Solar Generation; 27/03/2018 – Charlotte BizJournal: Duke Energy’s revived `Green Source’ renewables program gives advocates the blues; 10/05/2018 – DUKE HAS $2B EQUITY ISSUE TARGET IN 2018; 22/03/2018 – Duke Energy To Spend $11 Billion To Expand Renewables, Adapt To Low-carbon Future — MarketWatch; 18/04/2018 – DUKE’S BRUNSWICK 2 NUCLEAR REACTOR CUT TO 85% FROM 100%: NRC; 13/04/2018 – Duke Energy Ohio asks the Ohio Power Siting Board to move forward with its consideration of the Central Corridor Pipeline appli; 02/04/2018 – DUKE ENERGY WILL RETIRE CRYSTAL RIVER COAL-FIRED UNITS 1, 2; 25/05/2018 – Fitch Affirms Duke Energy Florida Project Finance, LLC; 27/04/2018 – Duke Energy Florida recognized as Tree Line USA utility for 12th consecutive year; 16/04/2018 – DUKE’S OCONEE 1 REACTOR UP TO 100% POWER FROM 0% FRIDAY: NRC

Analysts await Duke Energy Corporation (NYSE:DUK) to report earnings on February, 19. They expect $0.91 EPS, down 3.19% or $0.03 from last year’s $0.94 per share. DUK’s profit will be $648.72M for 24.61 P/E if the $0.91 EPS becomes a reality. After $1.65 actual EPS reported by Duke Energy Corporation for the previous quarter, Wall Street now forecasts -44.85% negative EPS growth.

Among 4 analysts covering Duke Energy (NYSE:DUK), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Duke Energy had 7 analyst reports since September 11, 2018 according to SRatingsIntel. Wells Fargo maintained Duke Energy Corporation (NYSE:DUK) rating on Monday, November 5. Wells Fargo has “Market Perform” rating and $88 target. Morgan Stanley maintained Duke Energy Corporation (NYSE:DUK) rating on Friday, September 21. Morgan Stanley has “Equal-Weight” rating and $85 target. The company was downgraded on Wednesday, January 9 by Bank of America. As per Monday, September 17, the company rating was maintained by Wells Fargo. The rating was maintained by Morgan Stanley with “Equal-Weight” on Tuesday, September 11. The stock of Duke Energy Corporation (NYSE:DUK) earned “Equal-Weight” rating by Barclays Capital on Monday, November 19. The rating was maintained by Morgan Stanley with “Equal-Weight” on Tuesday, February 12.

Investors sentiment decreased to 0.91 in Q3 2018. Its down 0.04, from 0.95 in 2018Q2. It dropped, as 46 investors sold DUK shares while 386 reduced holdings. 79 funds opened positions while 312 raised stakes. 408.54 million shares or 94.96% less from 8.11 billion shares in 2018Q2 were reported. Centre Asset Limited Liability reported 3,810 shares. Appleton Ptnrs Ma holds 0.03% or 3,064 shares. Brookstone Cap has 18,834 shares for 0.11% of their portfolio. Reliance Tru Communications Of Delaware reported 0.16% of its portfolio in Duke Energy Corporation (NYSE:DUK). Kbc Group Nv invested in 99,686 shares. Brave Asset Inc accumulated 3,454 shares. Ironwood Financial Llc reported 66 shares. Old Republic Corp reported 1.57% stake. Hl Fincl Service Ltd Liability Com reported 0.07% in Duke Energy Corporation (NYSE:DUK). Logan Capital Mngmt invested 0.11% of its portfolio in Duke Energy Corporation (NYSE:DUK). 61,090 are owned by Cetera Advisor Ltd Liability Company. Private Harbour Investment Management And Counsel Ltd accumulated 27,727 shares or 1.99% of the stock. Checchi Advisers Ltd Llc owns 8,404 shares. Greenwich Wealth Mgmt Ltd owns 2,646 shares for 0.04% of their portfolio. Wells Fargo Comm Mn invested 0.09% of its portfolio in Duke Energy Corporation (NYSE:DUK).

Braun Stacey Associates Inc increased E Trade Financial Corp Com New (NASDAQ:ETFC) stake by 47,384 shares to 286,390 valued at $15.00 million in 2018Q3. It also upped Ameren Corp Com (NYSE:AEE) stake by 101,715 shares and now owns 120,783 shares. Royal Caribbean Cruises Ltd Co (NYSE:RCL) was raised too.

More notable recent Duke Energy Corporation (NYSE:DUK) news were published by: Forbes.com which released: “In Spite Of Rising Revenues, Natural Disasters To Hit Duke’s Bottom Line In 2018 – Forbes” on February 13, 2019, also Benzinga.com with their article: “Earnings Scheduled For February 14, 2019 – Benzinga” published on February 14, 2019, Bizjournals.com published: “CBJ Morning Buzz: Changes in store for NC liquor laws?; New hotel opens in Steele Creek – Charlotte Business Journal” on February 13, 2019. More interesting news about Duke Energy Corporation (NYSE:DUK) were released by: Bizjournals.com and their article: “Duke Energy CEO asked about possible expansion, nuclear’s future at Charlotte Rotary Club: Here’s what she said. – Charlotte Business Journal” published on January 29, 2019 as well as Benzinga.com‘s news article titled: “Duke Energy Corporation (NYSE:DUK), (WKHS) – Workhorse CEO Updates Company’s Progress, SureFly Timeline – Benzinga” with publication date: January 15, 2019.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” on February 06, 2019, also Seekingalpha.com with their article: “UBS likes Lilly in premarket analyst action – Seeking Alpha” published on January 23, 2019, Nasdaq.com published: “First Week of ALNY September 20th Options Trading – Nasdaq” on January 25, 2019. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on February 08, 2019 as well as Nasdaq.com‘s news article titled: “New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2019 – Nasdaq” with publication date: January 16, 2019.

Investors sentiment decreased to 1.06 in Q3 2018. Its down 0.55, from 1.61 in 2018Q2. It dropped, as 28 investors sold Alnylam Pharmaceuticals, Inc. shares while 78 reduced holdings. 34 funds opened positions while 78 raised stakes. 86.92 million shares or 5.57% less from 92.05 million shares in 2018Q2 were reported. Essex Invest Ltd Liability Corporation, a Massachusetts-based fund reported 13,365 shares. The Germany-based Commerzbank Aktiengesellschaft Fi has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Raymond James Services Advisors Incorporated holds 8,693 shares. Alliancebernstein L P stated it has 49,688 shares. Amp Cap Invsts Limited has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Knott David M holds 0.01% or 500 shares in its portfolio. Kepos Capital Ltd Partnership has invested 0.07% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 12 West Capital Mgmt L P stated it has 735,000 shares. Federated Inc Pa reported 0.13% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Clarivest Asset Mgmt Ltd Liability Company stated it has 0.03% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Apg Asset Management Nv has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Hall Laurie J Trustee has invested 0.18% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Rhenman & Asset Mngmt invested in 1.51% or 171,950 shares. M&T Commercial Bank has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). State Street Corporation stated it has 2.39 million shares.

Since August 30, 2018, it had 0 buys, and 1 sale for $300,000 activity. $300,000 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by Greenstreet Yvonne on Thursday, August 30.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $8.96 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Duke Energy Corporation (NYSE:DUK) Institutional Positions Chart